(NASDAQ: ZBIO) Zenas Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 50.63%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.72%.
Zenas Biopharma's revenue in 2025 is N/A.On average, 2 Wall Street analysts forecast ZBIO's revenue for 2026 to be $2,031,880,219, with the lowest ZBIO revenue forecast at $511,522,293, and the highest ZBIO revenue forecast at $3,552,238,145. On average, 2 Wall Street analysts forecast ZBIO's revenue for 2027 to be $1,627,342,981, with the lowest ZBIO revenue forecast at $1,433,432,569, and the highest ZBIO revenue forecast at $1,821,253,392.
In 2028, ZBIO is forecast to generate $3,528,417,254 in revenue, with the lowest revenue forecast at $3,105,074,049 and the highest revenue forecast at $3,951,760,459.